But despite the recent dip, many analysts believe CSL shares are undervalued and present a solid long-term investment opportunity. Let's see what the experts say. Several factors have weighed on ...

CSL, the country’s largest pharmaceuticals group, has been forced to defend how much it is paying executives after investors delivered a so-called first strike against the remuneration plans ...

Carlisle Companies Stock Up 3.8 % CSL stock opened at $450.80 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.72 and a quick ratio of 2.29. The firm has a market ...

UBS analyst Laura Sutcliffe maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$340.00. The company’s shares closed yesterday at $191.55. According to ...

In a report released yesterday, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$329.62. The company’s shares closed today at $191.55.

CSL has pulled studies or trials on three therapies and says US regulators have raised manufacturing concerns about a key new treatment in rare late-stage setbacks for the biotechnology giant’s ...

Buy CSL near 424.4 target 459.23 stop loss @ 423.17 Details The technical summary data tells us to buy CSL near 424.4 with an upside target of 459.23. This data also tells us to set a stop loss @ ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell short of the market’s revenue expectations in Q3 CY2024, but sales rose 5.9% year on year to $1.33 billion. Its non-GAAP ...

(RTTNews) - At the Annual General Meeting, Paul McKenzie, Chief Executive Officer of CSL Ltd. (CSL.AX), reaffirmed the company's financial guidance for fiscal year 2025. The company still expects ...